On September 12, 2026, the International Society of Urological Pathology (ISUP) will host a “Multidisciplinary Expert Consultation Conference on Precision Biomarker Testing in Bladder and Prostate Cancer“, open to members and non-member clinicians and scientists in pathology, urology, oncology, and related fields. The conference will take place immediately preceding the 38th European Congress of Pathology (ECP 2026) in Stockholm, Sweden, and will be held in person without a hybrid format.

Meeting Objectives:

1. Review the current landscape and clinical implementation of biomarker testing in bladder and prostate cancer.
2. Establish standardized, evidence-based recommendations for biomarker testing, interpretation, and reporting.
3. Define optimal specimen requirements, pre-analytical considerations, and specimen selection strategies for biomarker testing.
4. Define the role, clinical indications, limitations, and validation requirements of liquid biopsy.
5. Define the current and future roles of artificial intelligence and digital pathology in biomarker assessment, including workflow integration and quality assurance.
6. Identify knowledge gaps and research priorities to guide future studies, clinical trials, and guideline development.

This Consensus will be Co-Chaired by ISUP members, Dr. Liang Cheng (Providence, RI, USA), and Dr. Geert van Leenders (Rotterdam, Netherlands).

Date and Time:  September 12, 2026, 7:30 am – 1:30 pm (Stockholm, Sweden)

Meeting Venue: Grand Hôtel Stockholm (Website: https://grandhotel.se/)

Address: Södra Blasieholmshamnen 8, 103 27 Stockholm, Sweden